Carl June, MD, shares his scientific journey, from medical research officer in the U.S. Navy to leader behind the first FDA-approved gene therapy, during his one-on-one conversation with ASGCT President Hans-Peter Kiem, MD, PhD. Welcome to the third episode of Giants of Gene Therapy!

Dr. June is a professor in immunotherapy in the Department of Pathology and Laboratory Medicine at University of Pennsylvania's Perelman School of Medicine, the director of the Center for Cellular Immunotherapy, and the director of the Parker Institute for Cancer Immunotherapy at Penn. He was instrumental in bringing CAR T cells to the clinic and receiving the first FDA approval for CAR T cell therapy in 2017. 

Dr. June is a prolific researcher who has published more than 500 manuscripts. He's received numerous awards and honors and has been the founder or co-founder of many companies involved in T cell therapies. His discoveries launched a new era of cancer treatment options. Dr. June has been an ASGCT member and Annual Meeting keynote speaker.

Music by: Steven O'Brien
https://www.steven-obrien.net/

"Making Progress"

(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)

Carl June, MD, shares his scientific journey, from medical research officer in the U.S. Navy to leader behind the first FDA-approved gene therapy, during his one-on-one conversation with ASGCT President Hans-Peter Kiem, MD, PhD. Welcome to the third episode of Giants of Gene Therapy!
Dr. June is a professor in immunotherapy in the Department of Pathology and Laboratory Medicine at University of Pennsylvania's Perelman School of Medicine, the director of the Center for Cellular Immunotherapy, and the director of the Parker Institute for Cancer Immunotherapy at Penn. He was instrumental in bringing CAR T cells to the clinic and receiving the first FDA approval for CAR T cell therapy in 2017. 
Dr. June is a prolific researcher who has published more than 500 manuscripts. He's received numerous awards and honors and has been the founder or co-founder of many companies involved in T cell therapies. His discoveries launched a new era of cancer treatment options. Dr. June has been an ASGCT member and Annual Meeting keynote speaker.
Music by: Steven O'Brien <a href="https://protect-us.mimecast.com/s/jcayCv2rxWtyKRVTQLe7p">https://www.steven-obrien.net/</a>
"Making Progress"
(Used for free under a Creative Commons Attribution 4.0 License: <a href="https://protect-us.mimecast.com/s/ibdECwpvyXUR92rIq1jwO">https://creativecommons.org/licenses/by/4.0/</a>)

The American Society of Gene & Cell Therapy is the premier membership organization for professionals working in cell and gene therapy. On this network, we're sharing exciting stories from our members and the greater scientific community.

The American Society of Gene &amp; Cell Therapy is the premier membership organization for professionals working in cell and gene therapy. On this network, we're sharing exciting stories from our members and the greater scientific community.

ASGCT Podcast Network

03 - Carl June, MD - Giants of Gene Therapy

Host Emily Walsh Martin, PhD, is joined by Chris Choi, PhD, Roswell Park Comprehensive Cancer Center's Senior Vice President of Industry Partnerships and Technical Director of the center’s new Good Manufacturing Practice (cGMP) Facility. Dr. Choi is also an associate professor of oncology. This wide-ranging conversation covers cell therapy development and manufacturing and how the growing Roswell Park Center is aiming to support sponsors in the CAR T and cell therapy space. Emily and Chris also discuss their experiences on cross-functional teams and how a program's research, manufacturing, and clinical elements must be knit together for success.

Music by: https://www.steven-obrien.net/
--------------------------
Bright New Morning - Steven O'Brien

(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)

Host Emily Walsh Martin, PhD, is joined by Chris Choi, PhD, Roswell Park Comprehensive Cancer Center's Senior Vice President of Industry Partnerships and Technical Director of the center’s new Good Manufacturing Practice (cGMP) Facility. Dr. Choi is also an associate professor of oncology. This wide-ranging conversation covers cell therapy development and manufacturing and how the growing Roswell Park Center is aiming to support sponsors in the CAR T and cell therapy space. Emily and Chris also discuss their experiences on cross-functional teams and how a program's research, manufacturing, and clinical elements must be knit together for success.
Music by: <a href="https://protect-us.mimecast.com/s/2tr6CrknqPT6KWqS7Xin0">https://www.steven-obrien.net/</a> -------------------------- Bright New Morning - Steven O'Brien
(Used for free under a Creative Commons Attribution 4.0 License: <a href="https://protect-us.mimecast.com/s/FOoyCv2rxWt4mR9fX52Pt">https://creativecommons.org/licenses/by/4.0/</a>)

cGMP and Building Cohesive Teams with Christopher Choi, PhD, Roswell Park Comprehensive Cancer Center - The Issue

This episode features a conversation between Dr. Roland Herzog and Dr. Joseph Glorioso. On January 1, 2025, Dr. Glorioso will begin his 5-year term as the Editor-in-Chief of Molecular Therapy, marking the end of Dr. Herzog’s successful tenure at the helm of the journal. Drs.Herzog and Glorioso engage in a wide-ranging conversation that touches on the history of Molecular Therapy, highlights from the gene and cell therapy field, and how Molecular Therapy will continue to grow and evolve under Dr. Glorioso’s leadership.

ASGCT is proud to present this episode of the Molecular Therapy Podcast in partnership with our upcoming Breakthroughs in Muscular Dystrophy conference on November 19th and 20th in Chicago, and virtually This event will provide an unparalleled opportunity to delve into the latest advancements in research on gene and cell therapies for muscular dystrophy. Learn more and register today at ASGCT.org/Breakthroughs.

In This Episode:

Dr. Roland Herzog
Editor-in-Chief of Molecular Therapy and Professor of Pediatrics, Riley Children's Foundation Professor of Immunology, and Director of the Gene and Cell Therapy Program at Indiana University

Dr. Joseph Glorioso
Professor, Department of Microbiology and Molecular Genetics and Department of Human Genetics at the University of Pittsburgh


'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.
www.scottbuckley.com.au

This episode features a conversation between Dr. Roland Herzog and Dr. Joseph Glorioso. On January 1, 2025, Dr. Glorioso will begin his 5-year term as the Editor-in-Chief of Molecular Therapy, marking the end of Dr. Herzog’s successful tenure at the helm of the journal. Drs.Herzog and Glorioso engage in a wide-ranging conversation that touches on the history of Molecular Therapy, highlights from the gene and cell therapy field, and how Molecular Therapy will continue to grow and evolve under Dr. Glorioso’s leadership.
ASGCT is proud to present this episode of the Molecular Therapy Podcast in partnership with our upcoming Breakthroughs in Muscular Dystrophy conference on November 19th and 20th in Chicago, and virtually This event will provide an unparalleled opportunity to delve into the latest advancements in research on gene and cell therapies for muscular dystrophy. Learn more and register today at <a href="ASGCT.org/Breakthroughs">ASGCT.org/Breakthroughs.</a>
In This Episode:
Dr. Roland Herzog Editor-in-Chief of Molecular Therapy and Professor of Pediatrics, Riley Children's Foundation Professor of Immunology, and Director of the Gene and Cell Therapy Program at Indiana University
Dr. Joseph Glorioso Professor, Department of Microbiology and Molecular Genetics and Department of Human Genetics at the University of Pittsburgh 
'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. <a href="https://protect-us.mimecast.com/s/CXOTCL9w1QUXqP0HBBFDP">www.scottbuckley.com.au</a>

A New Era of Molecular Therapy with Joseph Glorioso, PhD

Derek Jackson, vice president of cell and gene therapy product development at Pacira BioSciences, joins The Issue to take the program in a different direction.

We often focus our discussions on CGT for rare diseases. Most of the time, the teams of scientists working on the program don’t have any personal experience with the disease from their family, friends, or themselves.. but today we will talk about gene therapy development for a much more common disease: knee osteoarthritis. Moreover, the product we will be discussing is not only non-rare but also non-AAV. 

Music by: https://www.steven-obrien.net/
--------------------------
Bright New Morning - Steven O'Brien

(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)

Derek Jackson, vice president of cell and gene therapy product development at Pacira BioSciences, joins The Issue to take the program in a different direction.
We often focus our discussions on CGT for rare diseases. Most of the time, the teams of scientists working on the program don’t have any personal experience with the disease from their family, friends, or themselves.. but today we will talk about gene therapy development for a much more common disease: knee osteoarthritis. Moreover, the product we will be discussing is not only non-rare but also non-AAV. 
Music by: <a href="https://protect-us.mimecast.com/s/2tr6CrknqPT6KWqS7Xin0">https://www.steven-obrien.net/</a> -------------------------- Bright New Morning - Steven O'Brien
(Used for free under a Creative Commons Attribution 4.0 License: <a href="https://protect-us.mimecast.com/s/FOoyCv2rxWt4mR9fX52Pt">https://creativecommons.org/licenses/by/4.0/</a>)

03 - Carl June, MD - Giants of Gene Therapy

In 1 playlist(s)

ASGCT Podcast Network

Social links

Follow podcast

Recent clips